Skip to main content

Web Exclusives

Original Research, Clinical
Provider and Payer Perspectives on the Impact of the COVID-19 Pandemic on Patients With Opioid Use Disorder: Multi-Stakeholder In-Depth Interviews
Maher Abdel-Sattar, PharmD, MS, FAMCP; Seth Cook, PharmD, MS; Ann Wheeler, PharmD; William Mullen, PA-C, MPH; Brett Alyson Maiese, PhD, MHS; Christian Heidbreder, PhD, MA; William Santoro, MD, FASAM, DABAM
Read More
Breast Cancer
Radiation May Be Safely Omitted in Favorable-Risk Breast Cancer Patients Aged 50 to 69 Years
Read More
Online Only
Business, Original Research
A Retrospective Trend Analysis of Utilization, Spending, and Prices for Generic Statins in the US Medicaid Population, 1991-2022
Yiyu Chen, MS; Patricia R. Wigle, PharmD, PhD; Orson Austin, MD; Jeff Jianfei Guo, BPharm, PhD
Read More
FDA Approvals
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Read More
FDA Approvals
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Read More
FDA Approvals
Ogsiveo First Treatment FDA Approved for Desmoid Tumors
Read More
FDA Approvals
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Read More
FDA Approvals
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Read More
FDA Approvals
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Read More
FDA Approvals
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
Read More
Page 1 of 37
Results 1 - 10 of 367